The increased expression of p35 in DLBCL cells enhances the resistance to apoptosis induced by BTZ (the first proteasome inhibitor utilized as chemotherapeutic drug for the treatment of several types of cancers). The gene discussed is CDK5R1; the disease is diffuse large B-cell lymphoma.